Abstract O55 Figure 1

Abstract O55

Introduction

Early detection and removal of premalignant colorectal polyps with a high potential to progress to invasive cancer is important for incidence reduction. However, there is evidence that cancers in the proximal colon tend to be detected later than other subsites resulting in more advanced stage at diagnosis and lower survival. This study examined which polyp characteristics were independently associated with proximal colon cancer incidence.

Methods

Data were used from the All Adenomas study, which examined endoscopy and associated pathology data on ~30,000 individuals with at least one adenoma identified. Eligible participants underwent colonoscopy between 1984 and 2010 in one of 17 UK hospitals. Polyp characteristics at baseline colonoscopy, including number, size, histology, grade and location were obtained from the database. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of proximal colon adenocarcinoma. Time since baseline colonoscopy was used as the underlying time scale. HRs were mutually adjusted for polyp characteristics in addition to demographic- and colonoscopy-related confounders.

Results

Of the 27,812 (42.4% female) participants included in the analysis, 227 (0.82%) developed proximal colon cancer during a median follow-up of 9 years. Cumulative incidence over 15 years was 1.4% (95% CI: 1.2% - 1.6%). Proximal colon cancer incidence was higher among participants with ≥1 adenoma in the proximal colon at baseline, either solely or in addition to distal adenomas, compared to patients with only distal adenomas (HR 1.95, 95% CI: 1.46 – 2.62). The risk was also higher among those with ≥3 adenomas compared to those with <3 adenomas at baseline (HR 1.47, 95% CI: 1.04 – 2.08) and those with adenomas ≥10 mm compared to those with adenomas <10 mm (HR 1.47, 95% CI: 1.07 – 2.01). Neither adenoma histology nor grade were independently associated with the outcome.

Conclusions

Although lactulose increases SBWC by an amount close to that predicted by its osmotic load (130 ml) this did not significantly alter colonic water content. This may be due to its known rapid metabolism and suggests its laxative effect may be due to the stimulatory effects of products of fermentation. Ondansetron did not alter postprandial intestinal water nor reduce the effect of lactulose suggesting that its anti-diarrhoeal effect may be primarily due to altered colonic motility.

RISK FACTORS FOR PROXIMAL COLON CANCER: HOW INFORMATIVE ARE POLYP FINDINGS IN DETERMINING FUTURE RISK?

Conclusions

Although lactulose increases SBWC by an amount close to that predicted by its osmotic load (130 ml) this did not significantly alter colonic water content. This may be due to its known rapid metabolism and suggests its laxative effect may be due to the stimulatory effects of products of fermentation. Ondansetron did not alter postprandial intestinal water nor reduce the effect of lactulose suggesting that its anti-diarrhoeal effect may be primarily due to altered colonic motility.

Introduction

Serrated Polyposis Syndrome (SPS) is now known to be the commonest polyposis syndrome. Previous analyses for germline mutations have shown no consistent positive findings. To exclude other polyposis syndromes, new 2019 BSG guidelines advise gene panel testing if: the patient is under 50 years of age; if there are multiple affected individuals within a family; or if there is dysplasia within any of the polyps.

Methods

A database of patients with SPS according to the WHO 2019 criteria was established at the Oxford University Hospitals NHS Trust. Data collection began in 2010 and in total there are 192 SPS patients. The results of any patients sent for genetic testing were analysed.

Results

Out of 192 patients, 76 underwent genetic testing. The majority were tested for a hereditary colorectal cancer panel including MUTYH, APC, PTEN, SMAD4, BMPR1A, STK11 and Lynch syndrome mismatch repair genes. Of these, 14 had a positive genetic test result. Table 1 characterises patient with positive results.

Conclusions

7% (14/192) of SPS patients were affected by heterozygous germline mutations, higher than in previous series. To exclude other polyposis syndromes, new 2019 BSG guidelines advise gene panel testing if: the patient is under 50 years of age; if there are multiple affected individuals within a family; or if there is dysplasia within any of the polyps.
Abstract 057 Table 1

<table>
<thead>
<tr>
<th>Gene affected</th>
<th>Mutation</th>
<th>WHO type</th>
<th>Age at diagnosis</th>
<th>Clinical outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNF43</td>
<td>c.471 del G</td>
<td>Pathogenic variant</td>
<td>68</td>
<td>Cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>MUTYH</td>
<td>c.1187G&gt;A</td>
<td>I</td>
<td>70</td>
<td>Cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>APC</td>
<td>c.646-4T&gt;G</td>
<td>II</td>
<td>32</td>
<td>Cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>SMAD4</td>
<td>c.455-2A&gt;G</td>
<td>I</td>
<td>78</td>
<td>Upper GI endoscopic surveillance, HHT screening and cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>POLD1</td>
<td>c.346G&gt;A</td>
<td>I</td>
<td>70</td>
<td>Cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>CHEK2</td>
<td>c.1427C&gt;T</td>
<td>I</td>
<td>34</td>
<td>Annual PSA testing and cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>CHEK2</td>
<td>c.1100delC</td>
<td>I</td>
<td>68</td>
<td>Moderate risk breast screening and cascade genetic testing for at-risk relatives</td>
</tr>
<tr>
<td>MSH6</td>
<td>c.1054G&gt;A</td>
<td>I</td>
<td>30</td>
<td>No change</td>
</tr>
<tr>
<td>MSH6</td>
<td>c.2398G&gt;C</td>
<td>I</td>
<td>59</td>
<td>No change</td>
</tr>
<tr>
<td>MSH6</td>
<td>c.3026A&gt;T</td>
<td>I</td>
<td>36</td>
<td>No change</td>
</tr>
<tr>
<td>MSH2</td>
<td>c.835C&gt;G</td>
<td>I</td>
<td>37</td>
<td>No change</td>
</tr>
<tr>
<td>APC</td>
<td>c.347K&gt;A</td>
<td>II</td>
<td>54</td>
<td>No change</td>
</tr>
<tr>
<td>APC</td>
<td>c.2486C&gt;T</td>
<td>I</td>
<td>38</td>
<td>No change</td>
</tr>
<tr>
<td>NTHL1</td>
<td>c.512C&gt;T</td>
<td>II</td>
<td>52</td>
<td>No change</td>
</tr>
</tbody>
</table>

References


Neurogastroenterology

058 IS THE LOW FODMAP DIET EFFECTIVE IN THE LONG TERM? THE LARGEST MULTICENTRE PROSPECTIVE STUDY

1Anupam Rej*, 2Rachel L Buckle, 3Christian C Shaw, 4Nick Trott, 5Sebastian Advu-Tei, 2Anurag Agrawal, 2Joanna Mosey, 2Katie Sanders, 5Rupert Allen, 6Sophie Martin, 5Aimee Newton, 5Kelly Robinson, 5David Ephrick, 5Imran Aziz, 5David Sanders. 5Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK; 2Doncaster and Bassetlaw Hospitals NHS Trust, Ansthorpe Road, Doncaster, UK; 3University Hospital Lewisham, Lewisham High Street, London, UK; 4Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, UK; 5Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Wigginton Road, York, UK; 6Chesterfield Royal Hospital NHS Foundation Trust, Calow, Chesterfield, UK

Introduction

The low FODMAP diet (LFD) has been demonstrated to be effective in managing the symptoms of irritable bowel syndrome (IBS) in the short term. However, data remains limited on the long-term effects of this dietary therapy. The aim of this study was to assess the long-term effect of the LFD on symptom management and adherence.

Methods

Patients with IBS who had received LFD advice between 2012–2019 were prospectively recruited at 7 centres in the United Kingdom. Participants were invited to complete dietary questionnaires assessing the LFD at long term follow up (>6 months). Symptoms were assessed using a modified gastrointestinal symptom rating scale (0, none; 1, mild; 2, moderate; 3, severe).

Results

589 patients were approached, with 154 participants completing the study (76% female, mean age 51±15 years). The mean duration of follow up following initiation of the LFD was 42±28 months. A statistically significant improvement in abdominal pain (2.3±0.8 vs 1.2±0.9, p<0.001), abdominal bloating/distention (2.3±0.8 vs 1.4±1.0, p<0.001) and bowel urgency (2.0±1.1 vs 1.3±1.0, p<0.001) was noted following the LFD at long term versus baseline. 78% (n=120) of individuals reported following an adapted LFD at long term follow up. 60% (n=92) reported grains (wheat, rye, barley) as a trigger for their symptoms, with 64% (n=98) purchasing gluten or wheat free products in the long term.

Conclusion

This is the largest study demonstrating the efficacy of the LFD in the long term for individuals with IBS. Adherence to an adapted LFD appears to be good in the long term, with the majority of individuals reporting grains as a trigger and purchasing gluten or wheat free products to manage their symptoms.

059 MRI METHODS TO DEFINE COLONIC FUNCTION IN HEALTH AND CONSTIPATION

1Victoria Wilkinson-Smith*, 2Caroline Hoad, 3David Atkinson, 1Luca Marciani, 1Maura Corsetti, 3Mark Scott, 2Stuart Taylor, 1Penny Gowland, 1Robin Spiller. 1NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK; 2Centre For Medical Imaging, UCL, UK, London, UK; 3Neurogastroenterology Group, QMUL, London, UK

Background

RECLAIM is a multicentre study examining patients with functional constipation (FC) and IBS with constipation (IBS-C), along with healthy volunteers (HV) to correlate MRI findings with those from colonic manometry, and...